Phase 3 Recruiting Network
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in diff…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT03937635
Sites in Washington: - Providence Regional Cancer System-Aberdeen — Aberdeen, Washington
- MultiCare Auburn Medical Center — Auburn, Washington
- Overlake Medical Center — Bellevue, Washington
- PeaceHealth Saint Joseph Medical Center — Bellingham, Washington
- Harrison HealthPartners Hematology and Oncology-Bremerton — Bremerton, Washington
Phase 3 Recruiting Network
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of c…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04566328
Sites in Washington: - Providence Regional Cancer System-Aberdeen — Aberdeen, Washington
- PeaceHealth Saint Joseph Medical Center — Bellingham, Washington
- Harrison HealthPartners Hematology and Oncology-Bremerton — Bremerton, Washington
- Highline Medical Center-Main Campus — Burien, Washington
- Providence Regional Cancer System-Centralia — Centralia, Washington
Phase 3 Recruiting Network
This phase III trial compares three-drug induction regimens followed by double-or single-drug maintenance therapy for the treatment of newly diagnosed multiple myeloma in patients who are not receiving a stem cell transplant and are consid…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05561387
Sites in Washington: - Providence Regional Cancer System-Aberdeen — Aberdeen, Washington
- PeaceHealth Saint Joseph Medical Center — Bellingham, Washington
- Harrison Medical Center — Bremerton, Washington
- Providence Regional Cancer System-Centralia — Centralia, Washington
- Swedish Cancer Institute-Edmonds — Edmonds, Washington
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexam…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05552222
Sites in Washington: - NorthWest Medical Specialties, PLLC — Tacoma, Washington
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple m…
Sponsor: Celgene
NCT ID: NCT05519085
Sites in Washington: - VA Puget Sound Health Care System — Seattle, Washington
- Local Institution - 0293 — Seattle, Washington
- Local Institution - 0097 — Spokane, Washington
- Northwest Cancer Specialists, P.C. — Vancouver, Washington
Phase 3 Recruiting Industry
The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, inclu…
Sponsor: Kite, A Gilead Company
NCT ID: NCT06413498
Sites in Washington: - Swedish Cancer Institute — Seattle, Washington
- Fred Hutchinson Cancer Center — Seattle, Washington
Phase 3 Recruiting Industry
The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dex…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06208150
Sites in Washington: - Swedish Cancer Institute — Seattle, Washington
- Fred Hutchinson Cancer Research Center — Seattle, Washington
- NorthWest Medical Specialties, PLLC — Tacoma, Washington
Phase 3 Recruiting Industry
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney fail…
Sponsor: AbbVie
NCT ID: NCT06158841
Sites in Washington: - Northwest Medical Specialties Tacoma /ID# 276281 — Tacoma, Washington
Phase 3 Recruiting Industry
This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \[daratumumab, carfilzomib, and dexamethasone\], DPd \[daratumumab, pomalidomide, …
Sponsor: AstraZeneca
NCT ID: NCT07391657
Sites in Washington: - Research Site — Seattle, Washington
Phase 3 Recruiting Industry
This study is researching an experimental drug called linvoseltamab, also called REGN5458. Linvoseltamab has previously been studied by itself (without other cancer drugs) in participants who had advanced multiple myeloma that returned and…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT05730036
Sites in Washington: - University of Washington — Seattle, Washington
Phase 2 Recruiting Academic/Other
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE:…
Sponsor: American Society of Clinical Oncology
NCT ID: NCT02693535
Sites in Washington: - Northwest Medical Specialties — Bonney Lake, Washington
- Northwest Medical Specialties — Federal Way, Washington
- Northwest Medical Specialties — Gig Harbor, Washington
- Northwest Medical Specialties — Olympia, Washington
- Northwest Medical Specialties — Puyallup, Washington
Phase 2 Recruiting NIH
This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell \[CAR-T\] therapy) for multiple myelo…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06179888
Sites in Washington: - Swedish Cancer Institute-Edmonds — Edmonds, Washington
- Swedish Cancer Institute-Issaquah — Issaquah, Washington
- Fred Hutchinson Cancer Center — Seattle, Washington
- Swedish Medical Center-First Hill — Seattle, Washington
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT ID: NCT06297226
Sites in Washington: - Fred Hutchinson Cancer Center — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
This trial is a Phase 1b/2, open-label, multicenter study of AZD0120, a CD19/BCMA dual CAR T-cell therapy, in adult subjects with relapsed/refractory multiple myeloma.
Sponsor: AstraZeneca
NCT ID: NCT05850234
Sites in Washington: - Research Site — Edmonds, Washington
- Research Site — Seattle, Washington
Phase 2 Recruiting Industry
The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called r…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07266441
Sites in Washington: - NorthWest Medical Specialties, PLLC — Tacoma, Washington
Phase 1, Phase 2 Recruiting Industry
This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and ne…
Sponsor: Karyopharm Therapeutics Inc
NCT ID: NCT02343042
Sites in Washington: - Fred Hutch Cancer Center — Seattle, Washington
- Swedish Cancer Institute — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM) and chromosomal translocation t(11;14)…
Sponsor: BeOne Medicines
NCT ID: NCT04973605
Sites in Washington: - University of Washington — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
The main purpose of this study is to learn about the safety of linvoseltamab and to find out what is the best dose of linvoseltamab to give to patients with multiple myeloma and to look for any signs that linvoseltamab can effectively trea…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT03761108
Sites in Washington: - Swedish Cancer Institute — Seattle, Washington
Phase 2 Recruiting Academic/Other
This research study will determine the proportion of patients with lowest minimal residual disease (MRD) response obtainable after receiving 6 cycles of study treatment. Minimal residual disease is multiple myeloma cells below the level of…
Sponsor: University of Alabama at Birmingham
NCT ID: NCT05231629
Sites in Washington: - University of Washington — Seattle, Washington
Phase 2 Recruiting Industry
The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preventive) treatment phase, to better charac…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06500884
Sites in Washington: - University of Washington — Seattle, Washington
Phase 2 Recruiting Industry
This study is researching an investigational drug called linvoseltamab ("study drug") in participants at moderate risk of developing multiple myeloma (about 3 to 10% average annual risk), a group that consists of patients with precancerous…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06140524
Sites in Washington: - University of Washington — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and change in disease activity of ABBV-453 in adult participants with r…
Sponsor: AbbVie
NCT ID: NCT06953960
Sites in Washington: - Northwest Medical Specialties Tacoma /ID# 272506 — Tacoma, Washington
Phase 1, Phase 2 Recruiting Academic/Other
This phase I/II trial evaluates the safety and feasibility of early, response-based dose reduction of linvoseltamab in the treatment of patients multiple myeloma that has come back after a period of improvement (relapsed), that does not re…
Sponsor: Fred Hutchinson Cancer Center
NCT ID: NCT07181941
Sites in Washington: - Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Phase 1 Recruiting Industry
The main purpose of the study is to understand how safe and tolerable is elranatamab when given along with iberdomide. There are 2 parts to this study. Part 1 will look at how safe and tolerable is elranatamab when given with iberdomide. P…
Sponsor: Pfizer
NCT ID: NCT06215118
Sites in Washington: - Fred Hutchinson Cancer Center — Seattle, Washington
- University of Washington — Seattle, Washington
Phase 1 Recruiting Industry
Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, a…
Sponsor: AbbVie
NCT ID: NCT05650632
Sites in Washington: - Fred Hutchinson Cancer Center. /ID# 267940 — Seattle, Washington
- Northwest Medical Specialties Tacoma /ID# 267117 — Tacoma, Washington